title: Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema.
abstract: OBJECTIVE
  To determine whether a three day burst of a potent corticosteroid is more effective than a mild preparation used for seven days in children with mild or moderate atopic eczema.
  
  
  METHODS
  Randomised, double blind, parallel group study of 18 weeks' duration.
  
  
  METHODS
  13 general practices and a teaching hospital in the Nottingham area.
  
  
  METHODS
  174 children with mild or moderate atopic eczema recruited from general practices and 33 from a hospital outpatient clinic.
  
  
  METHODS
  0.1% betamethasone valerate applied for three days followed by the base ointment for four days versus 1% hydrocortisone applied for seven days.
  
  
  METHODS
  Primary outcomes were total number of scratch-free days and number of relapses. Secondary outcomes were median duration of relapses, number of undisturbed nights, disease severity (six area, six sign atopic dermatitis severity scale), scores on two quality of life measures (children's life quality index and dermatitis family impact questionnaire), and number of patients in whom treatment failed in each arm.
  
  
  RESULTS
  No differences were found between the two groups. This was consistent for all outcomes. The median number of scratch-free days was 118.0 for the mild group and 117.5 for the potent group (difference 0.5, 95% confidence interval -2.0 to 4.0, P=0.53). The median number of relapses for both groups was 1.0. Both groups showed clinically important improvements in disease severity and quality of life compared with baseline.
  
  
  CONCLUSIONS
  A short burst of a potent topical corticosteroid is just as effective as prolonged use of a milder preparation for controlling mild or moderate atopic eczema in children.
authors.affiliation: Centre of Evidence-Based Dermatology, Queen's Medial Centre, Nottingham NG7 2UH.
authors.forename: K S
authors.initials: KS
authors.lastname: Thomas
authors.forename: S
authors.initials: S
authors.lastname: Armstrong
authors.forename: A
authors.initials: A
authors.lastname: Avery
authors.forename: A Li Wan
authors.initials: AL
authors.lastname: Po
authors.forename: C
authors.initials: C
authors.lastname: O'Neill
authors.forename: S
authors.initials: S
authors.lastname: Young
authors.forename: H C
authors.initials: HC
authors.lastname: Williams
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D001624:Betamethasone Valerate / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002648:Child; D002675:Child, Preschool; D002755:Choice Behavior; D003876:Dermatitis, Atopic / Q000178:diet therapy* / Q000191:economics; D004311:Double-Blind Method; D004643:Emollients / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D007223:Infant; D008297:Male; D009824:Ointments / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics
chemical_list: D000893:Anti-Inflammatory Agents; D004643:Emollients; D009824:Ointments; D001624:Betamethasone Valerate; D006854:Hydrocortisone